Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

LiraglutideUnderstand the science

How a stroke trial explored insulin resistance

3 numbered sourcesSource years 2025, 2026

Peptides are short amino-acid chains joined by peptide bonds. Their sequences can let them engage receptors that respond to hormone signals. Liraglutide is a peptide that activates the GLP-1 receptor. A 2026 analysis of the LAMP trial explored whether the association between liraglutide and recurrent stroke differed with participants’ starting insulin resistance. [1]

The older primary trial randomized 636 adults in China who had type 2 diabetes and a recent minor ischemic stroke or a high-risk transient ischemic attack. Participants received standard care, with or without liraglutide according to assignment. Within 90 days, recurrent stroke occurred in 7.9% in the liraglutide group and 13.8% in the group receiving standard care alone. That is the whole-trial comparison under the study’s specific eligibility criteria. [2]

The later study included 510 participants for whom the relevant starting measurements were available. The researchers used a calculation based on fasting glucose and insulin to estimate insulin resistance. They grouped participants around a specified threshold and asked whether the apparent treatment effect was different between the groups. In the group with higher estimated resistance, recurrence occurred in 5.8% with liraglutide and 18.1% with standard care alone. The study did not find a significant benefit in the lower-resistance group. [1]

The statistical test suggested that the treatment comparisons differed by starting resistance. The analysis was post hoc. Participants were randomized to treatment in the main trial, while the subgroup analysis used a subset of participants and a threshold applied for the later research question. An observed difference in this setting can motivate a study designed in advance to test whether the threshold identifies people with different responses. [1, 2]

The U.S. Victoza label includes a cardiovascular risk reduction indication for adults with type 2 diabetes and established cardiovascular disease. The LAMP study addresses a narrower research setting just after a minor stroke or high-risk transient ischemic attack. Its subgroup result is evidence about that setting and a specific estimate of insulin resistance. [1, 3]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Liraglutide

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.